CTOs on the Move

HumanTouch

www.humantouch.com

 
Human Touch is the leading provider of high-quality, innovative lifestyle products, massage chairs, and experiences that deliver life-changing benefits. We have been making people feel better for over 35 years by developing state-of-the-art massage products containing patented massage systems that replicate techniques used by massage professionals. Our wellness solutions help to reduce muscle tension and pain caused by today`s hectic lifestyle so that people can do what they do - better. Combining advanced technology and attractive design, Human Touch innovations are perfectly suited for today`s modern and traditional living spaces. Our customers include serious athletes looking to recover from intensive ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Les Buday
Director of Cybersecurity Profile

Similar Companies

Franklin County Nursing Home

Franklin County Nursing Home is a Preston, ID-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Platte Valley Medical Center

Platte Valley Medical Center is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Platte Valley Medical Center is based in Brighton, CO. You can find more information on Platte Valley Medical Center at www.pvmc.org

Pacific Island Medical Inc

Pacific Island Medical Inc is a Kailua, HI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AcelRx

AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.

Abridge

Abridge helps people stay on top of their health, one conversation at a time. We help people capture the details of their care so they can follow through on doctor`s recommendations and gain more peace of mind throughout their health journey.